1632.70
1.70%
Deven Choksey
We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 25% / 46.9% / 57.5% for the period of FY26-FY28E. The company is currently trading at 28x FY28E and we value the company at a PE of 32x FY28E EPS, implying a target price of INR 1,426 with the upside of 12.2%.
Tatva Chintan Pharma Chem Ltd. is trading above its 200 day SMA of 1397.4
More from Tatva Chintan Pharma Chem Ltd.
Recommended